Results 21 to 30 of about 133,463 (299)

Atmospheric mixing ratios of methyl ethyl ketone (2-butanone) in tropical, boreal, temperate and marine environments [PDF]

Atmospheric Chemistry and Physics, 2016
Methyl ethyl ketone (MEK) enters the atmosphere following direct emission from vegetation and anthropogenic activities, as well as being produced by the gas-phase oxidation of volatile organic compounds (VOCs) such as n-butane. This study presents the
A. M. Yáñez-Serrano, A. M. Yáñez-Serrano, A. M. Yáñez-Serrano, A. C. Nölscher, A. C. Nölscher, E. Bourtsoukidis, B. Derstroff, N. Zannoni, V. Gros, M. Lanza, J. Brito, S. M. Noe, E. House, C. N. Hewitt, B. Langford, E. Nemitz, T. Behrendt, T. Behrendt, J. Williams, P. Artaxo, M. O. Andreae, M. O. Andreae, J. Kesselmeier   +22 more
doaj   +1 more source

mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. [PDF]

PLoS ONE, 2014
Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors.
Sean T Bailey, Bing Zhou, Jeffrey S Damrauer, Bhavani Krishnan, Harper L Wilson, Aleisha M Smith, Mingqing Li, Jen Jen Yeh, William Y Kim   +8 more
doaj   +1 more source

PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK

Cell Reports, 2021
Summary: Flux through the RAF-MEK-ERK protein kinase cascade is shaped by phosphatases acting on the core components of the pathway. Despite being an established drug target and a hub for crosstalk regulation, little is known about dephosphorylation of ...
Eunice Cho, Hua Jane Lou, Leena Kuruvilla, David A. Calderwood, Benjamin E. Turk   +4 more
doaj   +1 more source

Oncolytic Effects of a Novel Influenza A Virus Expressing Interleukin-15 from the NS Reading Frame [PDF]

, 2012
Oncolytic influenza A viruses with deleted NS1 gene (delNS1) replicate selectively in tumour cells with defective interferon response and/or activated Ras/Raf/MEK/ERK signalling pathway.
Martin Michaelis, Muster Thomas, Joachim Seipelt, Markus Wolschek (167359), Martin Michaelis (23843), Marijke van Rikxoort (167355), Doerr, Hans Wilhelm, Wolschek Markus, Seipelt Joachim, Hans Wilhelm Doerr (17928), Andrej Egorov (167364), Thomas Muster, Hans Wilhelm Doerr, Jindrich Cinatl, Thomas Muster (167361), Muster, Thomas, Doerr Hans Wilhelm, Seipelt, Joachim, Joachim Seipelt (30928), Egorov Andrej, Cinatl Jindrich, Michaelis, Martin, Cinatl, Jindrich, Egorov, Andrej, Markus Wolschek, van Rikxoort, Marijke, Rikxoort, Marijke van, Andrej Egorov, van Rikxoort Marijke, Jindrich Cinatl Jr (167368), Wolschek, Markus, Marijke van Rikxoort, Michaelis Martin   +32 more
core   +2 more sources

Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report

Drugs in Context, 2019
Systemic treatment for metastatic melanoma has advanced dramatically in recent years with an impressive increase in the rate of overall survival. The two main different strategies are targeted therapies (i.e.
Sonia Brugnara , Mariacristina Sicher, Elena Maria Bonandini , Mattia Barbareschi, Carlo Renè Girardelli, Orazio Caffo   +5 more
doaj   +1 more source

IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA. [PDF]

PLoS ONE, 2016
Oncogenic activation of Ras/MEK downregulates the expression of interferon regulatory factor 1 (IRF1), which is a prerequisite for oncolytic viruses to replicate in cancer cells [1].
Yumiko Komatsu, Leena Derwish, Kensuke Hirasawa   +2 more
doaj   +1 more source

Basal-Subtype and MEK-Pl3K Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition [PDF]

, 2009
Specific inhibitors of MEK have been developed that efficiently inhibit the oncogenic RAF-MEK-ERK pathway. We employed a systems-based approach to identify breast cancer subtypes particularly susceptible to MEK inhibitors and to understand molecular ...
Bayani, Nora, Bhattacharya, Sanchita, Knight, Zachary, Gascard, Philippe, Spellman, Paul T., Kuo, Wen-Lin, Siwak, Doris, Parvin, Bahram, McCormick, Frank, Heiser, Laura M., Wyrobek, Andrew J., Bissell, Mina J., Korn, W. Michael, Wang, Nicholas J., Neve, Richard M., Feiler, Heidi S., Gendelman, Rina, Gray, Joe W., Mirzoeva, Olga K., Shokat, Kevan M., Das, Debopriya, Mills, Gordon B.   +21 more
core   +1 more source

Immunological effects of BRAF+MEK inhibition

OncoImmunology, 2018
Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is ...
Paolo A. Ascierto, Reinhard Dummer
doaj   +1 more source

Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies

Medicina, 2019
The few therapeutic strategies for advance hepatocellular carcinoma (HCC) on poor knowledge of its biology. For several years, sorafenib, a tyrosine kinase inhibitors (TKI) inhibitor, has been the approved treatment option, to date, for advanced HCC ...
Antonio Gnoni, Antonella Licchetta, Riccardo Memeo, Antonella Argentiero, Antonio G. Solimando, Vito Longo, Sabina Delcuratolo, Oronzo Brunetti   +7 more
doaj   +1 more source

DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells

Epigenetics, 2023
Though DNMTs inhibitors were widely used in myelodysplastic syndrome and leukaemia, their application in solid tumours has been limited by low response rate and lack of optimal combination strategies.
Zhangqian Chen, Lin Zhang, Yang Yang, Haiming Liu, Xiaoyu Kang, Yongzhan Nie, Daiming Fan   +6 more
doaj   +1 more source